CJC-1295 vs MOTS-c
Compare the research profiles of CJC-1295 and MOTS-c. Read the individual guides for evidence and limitations.
How to interpret this comparison
This page summarizes database profiles and has not yet received a study-by-study editorial review. These compounds are filed under different research categories, so a direct treatment comparison may not answer a meaningful clinical question. Use the linked guides and primary sources to evaluate a specific claim.
How to read peptide studiesCJC-1295
CJC-1295 (with or without DAC)
growth-hormone
Phase 2 Clinical Trials
not-approved
MOTS-c
MOTS-c (Mitochondrial ORF of the 12S rRNA Type-c)
mitochondrial
Preclinical
not-approved
Detailed Comparison
| Aspect | CJC-1295 | MOTS-c |
|---|---|---|
| Overview | A growth hormone releasing hormone (GHRH) analog that stimulates GH release. Available with DAC (Drug Affinity Complex) for extended half-life or without for shorter action.... | A mitochondrial-derived peptide described as an "exercise mimetic" that may improve glucose metabolism and physical stamina even without training. Naturally produced during exercise.... |
| Research topics (not established benefits) |
|
|
| Side Effects |
|
|
| Mechanism | Mimics GHRH to stimulate the pituitary gland to produce and release growth hormone. The DAC version binds to albumin for prolonged effect.... | Encoded in mitochondrial DNA, MOTS-c activates AMPK pathway and improves glucose uptake in skeletal muscle. May mimic some metabolic benefits of exerc... |
Frequently Asked Questions
Does a comparison establish which treatment is better?
Only appropriately designed evidence for the same clinical question can support that conclusion. Database categories and mechanisms alone cannot rank treatments.
Does this page establish that these compounds can be combined?
No. This page does not assess interactions or the benefit and safety of combined use. Individual studies cannot establish the effects of a combination.